TRDA
Entrada Therapeutics Inc
NASDAQ · Biotechnology
$10.60
+0.53 (+5.26%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 206.54M | 42.90M | 41.05M | 39.56M |
| Net Income | 64.31M | 8.98M | 10.98M | 8.24M |
| EPS | — | — | — | — |
| Profit Margin | 31.1% | 20.9% | 26.8% | 20.8% |
| Rev Growth | — | +8.9% | +15.8% | -1.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 40.22M | 40.33M | 38.74M |
| Total Equity | — | 221.82M | 201.28M | 228.47M |
| D/E Ratio | — | 0.18 | 0.20 | 0.17 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 49.76M | 15.57M | 16.71M | 15.93M |
| Free Cash Flow | — | 11.03M | 8.57M | 10.42M |